

## NSX Announcement: Addendum to 2013 Annual Report

SYDNEY, Australia, 26<sup>th</sup> October, 2013 – IQnovate Ltd (NSX: IQN, OTC: IQNDY, GXG: IQN)

Following are corrections to the release of 2013 Annual Report to the NSX on 27<sup>th</sup> September 2013,

- 1) Page 29
  - Note 15
    - the quantity of shares should read 37,455,890 instead of 37,527,890
  - Note 15 (a)
    - Shares issued at 20 February 2012 should read 1,908,500 instead of 1,980,500
    - Shares “At the end of the reporting period” should read 37,455,890 instead of 37,527,890
- 2) Page 9
  - Directors’ Report

Under “Indemnifying Officers or Auditor”, the paragraph be replaced with the following:  
“During or since the end of the financial year, the company has entered into agreements to indemnify directors, and paid \$1,474 in insurance premiums for Directors & Officers coverage insurance, which includes cover for these indemnifications.”

These changes have been made in the Annual Report accompanying the Notice to Members for the 2013 Annual General Meeting.

Spiro Sakiris – Company Secretary

### *Safe Harbor Statement*

*Any statements in this press release that relate to the Company's expectations are forward-looking statements, within the meaning of the Private Securities Litigation Reform Act. The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees. Since this information may involve risks and uncertainties and are subject to change at any time, the Company's actual results may differ materially from expected results. Additional risks associated with IQnovate's business can be found in its periodic filings with the National Stock Exchange of Australia.*

SOURCE IQnovate Limited

***IQnovate Ltd*** is a life science organisation, providing intellectual property asset management services and scientific advice to the global Biopharmaceutical industry.

*Whether the asset is a pharmaceutical, medical device, technology platform or a compound in development, IQNovate will effectively manage your asset through its complete life cycle, from clinical trials right through to maturity.*

*IQNovate clients are pharmaceutical, biotechnology, medical device companies as well as financial institutions, academic and government organisations.*